OncoMatch/Clinical Trials/NCT05013255
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
Is NCT05013255 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pioglitazone 15mg and Pioglitazone 30 mg for breast cancer.
Treatment: Pioglitazone 15mg · Pioglitazone 30 mg — The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Required: PR (PGR) positive
Prior therapy
Must have received: chemotherapy — neoadjuvant
no prior therapies besides chemotherapy in the neoadjuvant setting
Lab requirements
Blood counts
hemoglobin within normal institutional limits (or >10?)
Kidney function
serum creatinine within normal institutional limits
Liver function
liver function (ast and alt, alk phosphatase, total bilirubin) within normal limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- West Virginia University Cancer Institute · Morgantown, West Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify